[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Regend Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":117},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,69,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100620303","early-phase-1-treatment-of-chronic-obstructive-pulmonary-disease-copd-by-regend007-cell-therapy-100620303",false,"NCT07355868","Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy","An Exploratory Clinical Study on the Intravenous Infusion of REGEND007 (Generic Airway Basal Layer Stem Cells) for Treatment of Chronic Obstructive Pulmonary Disease (COPD)","Inclusion Criteria:\n\n* Gender is not restricted; when signing the informed consent form, the age should be between 40 and 80 years old (inclusive of the boundary values);\n* Diagnosed with COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) in 2025;\n* During the screening process, the six-minute walk test should be ≥ 150 meters and \\\u003C 600 meters;\n* Voluntarily sign the informed consent form, be able to cooperate with the completion of the research-related procedures and examinations, and be able to describe or record the changes in the condition in a relatively complete manner.\n\nExclusion Criteria:\n\n* Female subjects who are pregnant, breastfeeding, or planning to become pregnant within one year after using this product; or male subjects whose spouses are planning to become pregnant.\n* Subjects evaluated by the investigator at the time of screening have a survival period of less than one year.\n* Subjects with a current or past history of malignant tumors (excluding non-melanoma skin cancer, cervical cancer in situ, bladder cancer, thyroid cancer, and breast cancer, etc., which have a disease-free survival of more than five years and are judged by the investigator to have a relatively weak invasiveness) at the time of screening.\n* Subjects diagnosed with pneumonia (including bacterial, fungal, or viral pneumonia) within 4 weeks before screening.\n* Subjects who have experienced more than 4 episodes of moderate to severe acute exacerbation of COPD and required hospitalization within 1 year before screening.\n* Subjects who have one or more results of pathogen or serological tests (nucleic acid, antigen, virus culture, specific IgG antibody levels) reporting novel coronavirus infection, or suspected novel coronavirus infection (manifesting symptoms such as fever, headache, fatigue, joint pain, runny nose, sore throat, and persistent cough, and the disease course is consistent with the prevalent strain) within 4 weeks before screening.\n* Subjects with a history of invasive or non-invasive mechanical ventilation at the time of screening.\n* Subjects evaluated by the investigator at the time of screening have active pulmonary tuberculosis, poorly controlled bronchial asthma, acute pulmonary embolism, severe pulmonary hypertension \\[cardiac ultrasound examination \\> 70 mmHg\\], etc.\n* Subjects with severe non-pulmonary systemic diseases within 6 months before screening and evaluated by the investigator as not suitable to participate in this study, such as diabetic ketoacidosis or hyperosmolar coma, acute myocardial infarction, unstable angina pectoris, NYHA heart failure grade III\u002FIV, stroke, liver cirrhosis with severe liver dysfunction, severe renal insufficiency, etc.\n* Subjects with severe anemia, or controlled poorly granulocytopenia or thrombocytopenia at the time of screening.\n* Subjects with a history of suicidal risk, psychiatric history or epilepsy history at the time of screening.\n* Subjects with severe malnutrition at the time of screening.\n* Subjects with 12-lead electrocardiogram showing severe arrhythmias (such as ventricular tachycardia, supraventricular tachycardia, atrial fibrillation, atrial flutter, etc.) or abnormal conduct at II degree and above of the heart.\n* Subjects who have participated in other clinical trials with intervention measures or received other biological agent treatment within 4 weeks before screening.\n* Researchers, collaborating researchers, research coordinators, researchers participating in the study, or employees of the research center or their family members of the aforementioned personnel.\n* Subjects considered by the investigator to be unsuitable for participation in the trial (increasing the risk of the subjects or interfering with the clinical trial).","ALL","40 Years","80 Years",{"count":20,"type":21},12,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow. In a large number of patients, diffusion function is impaired along with the progression of disease. REGEND007 cell therapy, comprised of airway basal cells with ability to regenerate lung tissue, is promising to COPD treatment. A prospective, single-arm, dose-escalation exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of different doses of REGEND007 cell therapy administered by intravenous infusion in the treatment of COPD, and to recommend appropriate treatment doses for subsequent clinical studies.",[27],"Chronic Obstructive Pulmonary Disease (COPD)","RECRUITING","2026-03-19",{"date":31,"type":32},"2026-03-23","ACTUAL",{"date":29,"type":32},{"date":35,"type":21},"2026-12-15",{"name":37,"class":38},"Regend Therapeutics","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":39},"100614145","phase-1-a-study-of-regend003-on-patients-with-type-2-diabetes-mellitus-t2dm-and-chronic-kidney-disease-ckd-100614145","NCT07275788","A Study of REGEND003 on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)","An Exploratory Study of REGEND003 Kidney Progenitor Cells on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)","Inclusion Criteria:\n\n* Male or female, aged 30 to 75 years at the time of signing the informed consent form;\n* Diagnosed with Type 2 Diabetes Mellitus for at least 1 year;\n* Diagnosed with Chronic Kidney Disease (CKD);\n* Voluntarily sign the informed consent form, be able to cooperate in completing study-related procedures and examinations, capable of adequately recording or describing changes in their condition, and demonstrate strong compliance.\n\nExclusion Criteria:\n\n* Females who are pregnant, nursing, or planning to be pregnant within a year after using this product (or males whose spouse planning to be pregnant);\n* At the time of screening, subject who is positive in each of treponema pallidum antibody (TP-Ab), human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody test.\n\nHepatitis B virus carriers with stable current condition can be enrolled. Cured hepatitis C patients with negative result in HCV ribonucleic acid (RNA) test can be enrolled as well.\n\n* Presence of a current or prior history of malignant tumor at screening (with the exception of those with disease-free survival for more than 2 years, or malignancies deemed to be of low aggressiveness as assessed by the investigator).\n* Patients with Type 1 Diabetes Mellitus;\n* Patients undergoing regular hemodialysis or peritoneal dialysis;\n* Presence of severe acute complications of diabetes or CKD requiring hospitalization within 2 weeks prior to screening;\n* Presence of more than one episode of hypoglycemic coma (blood glucose ≤3.9 mmol\u002FL) within 1 month prior to screening;\n* Patients intolerant to renal puncture\u002Fintrarenal injection procedures;\n* Patients with diagnosis of acute kidney injury, congenital or hereditary kidney diseases, renal atrophy, or other renal conditions deemed ineligible by the investigator, as well as patients with a history of kidney transplantation at screening;\n* Presence of severe systemic diseases within 6 months prior to screening and judged by the investigator as unsuitable for the study;\n* Patients requiring long-term anticoagulant or antiplatelet therapy who, in the investigator's judgment, cannot discontinue medication 1 week prior to renal puncture\u002Fintrarenal injection procedures;\n* Patients with suicidal risk, history of psychiatric disorders, or history of epilepsy at screening;\n* Patients with severe arrhythmias or heart conduction disorders (degree II or above) in 12-lead ECG test at screening;\n* Patients participated in other clinical trials with interventions within 1 month prior to screening;\n* Subject with assessed survival time of less than 1 year by investigators at screening;\n* Investigators, co-investigators, study coordinators, employees of participating investigators or research centers, or family members of the above individuals;\n* Any condition that, in the investigator's judgment, may increase subject risk or interfere with the clinical trial.","30 Years","75 Years",{"count":50,"type":21},15,[52],"PHASE1","REGEND003, which consists of human kidney progenitor cells, demonstrates promising potential in repairing kidney injury. The purpose of this study is to assess the saftey and tolerability of REGEND003 on patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. It is an exploratory study with multi-centered, randomized, controlled, single-blinded, dose-escalated designs.",[55],"Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)",[57,58,59,60],"Type 2 Diabetes Mellitus","Chronic Kidney Disease","Cell Therapy","Kidney Progenitor Cells","2026-03-16",{"date":63,"type":32},"2026-03-17",{"date":65,"type":32},"2026-01-08",{"date":67,"type":21},"2027-12",{"name":37,"class":38},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":39},"100620618","early-phase-1-treatment-of-idiopathic-pulmonary-fibrosis-ipf-by-regend007-cell-therapy-100620618","NCT07359963","Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell Therapy","An Exploratory Clinical Study on the Intravenous Infusion of REGEND007 (Generic Airway Basal Layer Stem Cell Preparation) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).","Inclusion Criteria:\n\n* Gender is not restricted. When signing the informed consent form, the age should be between 40 and 80 years old (inclusive of the boundary value).\n* Diagnosed with idiopathic pulmonary fibrosis (IPF).\n* During the screening process, the six-minute walk test should be ≥ 150 meters and \\\u003C 600 meters; or the lung function FVC should be \\> 30% of the predicted value.\n* Voluntarily sign the informed consent form, be able to cooperate with the completion of research-related procedures and examinations, and be able to comprehensively describe or record the changes in the condition.\n\nExclusion Criteria:\n\n* Female subjects who are pregnant, breastfeeding, or planning to become pregnant within one year after using this product; or male subjects whose partner is planning to become pregnant.\n* Subjects selected during the screening whose estimated survival period is less than one year.\n* Subjects selected during the screening who have a current or past history of malignant tumors (excluding malignant tumors with a disease-free survival of more than five years and judged by the researcher to have a relatively mild invasiveness, such as non-melanoma skin cancer, invasive cervical cancer, bladder cancer, thyroid cancer, and breast cancer, etc.).\n* Subjects selected within 4 weeks before diagnosis of pneumonia (including bacterial, fungal or viral pneumonia).\n* Subjects selected within 4 weeks before an acute exacerbation of IPF.\n* Subjects selected within 4 weeks before having one or more results reported by pathogenological or serological tests (nucleic acid, antigen, virus culture, specific IgG antibody levels) indicating novel coronavirus infection, or suspected novel coronavirus infection (manifesting symptoms such as fever, headache, fatigue, joint pain, runny nose, sore throat, and persistent cough, and the disease course is consistent with the prevalent strain).\n* Subjects selected within 4 weeks before having a history of invasive or non-invasive mechanical ventilation.\n* Subjects selected during the screening who have active pulmonary tuberculosis, poorly controlled bronchial asthma, acute pulmonary embolism, severe pulmonary hypertension \\[cardiac ultrasound examination \\> 70 mmHg\\], etc.\n* Subjects selected within 6 months before having a serious non-pulmonary systemic disease and judged by the researcher as not suitable to participate in this study, such as diabetes with ketoacidosis or hyperosmolar coma, acute myocardial infarction, unstable angina pectoris, NYHA heart failure grade III\u002FIV, stroke, liver cirrhosis with severe liver dysfunction, severe renal insufficiency, etc.\n* Subjects selected during the screening who have severe anemia, or controlled poorly granulocytopenia or thrombocytopenia.\n* Subjects selected during the screening who have a history of suicide risk, psychiatric history or epilepsy history.\n* Subjects selected during the screening who have severe malnutrition.\n* Subjects selected during the screening whose 12-lead electrocardiogram shows severe arrhythmias (such as ventricular tachycardia, supraventricular tachycardia, atrial fibrillation, atrial flutter, etc.) or second-degree and above conduction abnormalities of the heart.\n* Subjects selected within 4 weeks before participating in other clinical trials with intervention measures or using other biological agents for treatment.\n* Researchers, collaborating researchers, research coordinators, researchers participating in the study or employees of the research center or their family members.\n* Subjects selected during the screening who the researcher considers unsuitable to participate in the trial (increasing the risk for the subjects or interfering with the clinical trial).",{"count":20,"type":21},[24],"This study is a prospective, single-arm, dose-escalation exploratory clinical trial to investigate the safety, tolerability and preliminary efficacy of REGEND007 stem cell preparation administered by intravenous infusion in the treatment of idiopathic pulmonary fibrosis (IPF), with a follow-up period of 12 weeks.",[80],"Idiopathic Pulmonary Fibrosis (IPF)","NOT_YET_RECRUITING","2026-01-13",{"date":84,"type":32},"2026-01-22",{"date":86,"type":21},"2026-02-15",{"date":88,"type":21},"2027-06-15",{"name":37,"class":38},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":39},"100611385","early-phase-1-treatment-of-pediatric-bronchiolitis-obliterans-by-airway-basal-stem-cells-100611385","NCT07239895","Treatment of Pediatric Bronchiolitis Obliterans by Airway Basal Stem Cells","Exploratory Study of Airway Basal Stem Cells on Treatment of Pediatric Bronchiolitis Obliterans","Inclusion Criteria:\n\n* Males and females, aged between 28 days and 18 years;\n* Diagnosed with bronchiolitis obliterans according to the guidelines;\n* Meeting at least one of the following: FEV1 \\\u003C 55% of predicted value; requiring continuous assisted mechanical ventilation or oxygen therapy;\n* None of acute infections within the past four weeks;\n* Tolerating bronchoscopy;\n* The child and\u002For parent(s) provide informed consent, and are able to understand and adhere to scheduled visits, treatments, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n* Subjects with bronchiolitis obliterans syndrome (BOS) who are on a current cGVHD treatment regimen at screening.\n* At the time of screening, subject who is positive in each of treponema pallidum antibody (TP-Ab), human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody test. Hepatitis B virus carriers with stable current condition can be enrolled. Cured hepatitis C patients with negative result in HCV ribonucleic acid (RNA) test can be enrolled as well.\n* Subject who is assessed to have major lung diseases other than BO by investigators at screening or who has other severe systemic diseases within 6 months prior to screening and is considered to be unsuitable for this study by investigators.\n* Presence of severe coagulation dysfunction at screening and may compromise the safety of bronchoscopy in the investigator's judgment.\n* Subjects requiring long-term maintenance anticoagulant therapy or antiplatelet aggregation therapy, and for whom, in the investigator's assessment, the medication cannot be discontinued within a week prior to cell collection and infusion.\n* Subjects with suicide risk or a history of psychiatric disorders at screening.\n* Participation in another interventional clinical study within 3 months prior to screening.\n* Poor compliance, making him or her difficult to complete the study.\n* Subjects who is considered to be unsuitable for this study in in the opinion of the investigator.","28 Days","18 Years",{"count":20,"type":21},[24],"Bronchiolitis obliterans (BO) is a chronic lung disease which was initiated with injury of the bronchiolar epithelium and resulted in nonuniform luminal obliteration or narrowing. Among children, the most common form of BO is post-infectious BO with a lack of treatment guidelines or standard therapy. In this study, an open, single-armed study is performed to preliminarily evaluate the safety and efficacy of airway basal stem cells on treatment of pediatric BO.",[103],"Pediatric Bronchiolitis Obliterans",[105,106,107,108],"Airway Basal Stem Cells","Bronchiolitis obliterans","Bronchiolar Epithelium","Pedatric Bronchiolitis Obliterans","2026-01-12",{"date":111,"type":32},"2026-01-14",{"date":113,"type":32},"2025-11-11",{"date":115,"type":21},"2027-11",{"name":37,"class":38},""]